We are developing unique analogs of the body’s natural gastrointestinal hormone – uroguanylin - a key regulator of normal physiology.Learn more about Synergy’s Drug Pipeline
We have an experienced management team with industry expertise and a proven background of execution.View our management team
Our approach is based on a key gastrointestinal hormone the body naturally produces to regulate normal digestive functioning - uroguanylin. Synergy scientists have discovered and developed two unique analogs of uroguanylin - plecanatide and SP-333 - designed to mimic the natural hormone's activity and target a variety of gastrointestinal conditions.Learn more about Synergy's Approach
Both our lead drug, plecanatide, and our next-generation candidate, SP-333, are proprietary analogs of the body’s naturally occurring gastrointestinal (GI) hormone, uroguanylin, and represent a novel approach to the treatment of GI diseases and disorders. Plecanatide is in late stage clinical trials for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). SP-333 has successfully completed a phase 2 study in patients with opioid-induced constipation (OIC) and is currently being studied for treatment of ulcerative colitis (UC).Learn More about Synergy's Drug Pipeline
|Compound||Indication||Pre-Clinical||Phase 1||Phase 2||Phase 3||Marketed|
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders.